A similar approach combining serum biomarkers TNFR1, NGAL, and complement C3a with clinical variables improved the prediction of CKD progression and mortality in a cohort of 139 CKD patients, unfortunately also without any validation [26]. This evidence concerns the gene LCN2 and chronic kidney disease.